Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.2.1.26 (
invertase
)
4,927
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A nontransformed rat jejunal crypt cell line (IEC-6) expresses transforming growth factor type beta 1 (
TGF-beta
1) mRNA, secretes latent 125I-labeled
TGF-beta
1 competing activity into culture medium, and binds 125I-labeled
TGF-beta
1 to specific, high-affinity (Kd = 3.7 pM) cell surface receptors. IEC-6 cell growth is markedly inhibited by
TGF-beta
1 and
TGF-beta
2 with half-maximal inhibition occurring between 0.1 and 1.0 ng of
TGF-beta
1 per ml.
TGF-beta
1-mediated growth inhibition is not associated with the appearance of biochemical markers of enterocyte differentiation such as alkaline phosphatase expression and
sucrase
activity.
TGF-beta
1 (10 ng/ml) increases steady-state levels of its own mRNA expression within 8 hr of treatment of rapidly growing IEC-6 cells. In freshly isolated rat jejunal enterocytes that are sequentially eluted from the crypt villus axis,
TGF-beta
1 mRNA expression is most abundant in terminally differentiated villus tip cells and least abundant in the less differentiated, mitotically active crypt cells. We conclude that
TGF-beta
1 is an autoregulated growth inhibitor in IEC-6 cells that potentially functions in an autocrine manner. In the rat jejunal epithelium,
TGF-beta
1 expression is most prominently localized to the villus tip--i.e., the region of the crypt villus unit that is characterized by the terminally differentiated phenotype. These data suggest that
TGF-beta
1 may function in coordination of the rapid cell turnover typical for the intestinal epithelium.
...
PMID:Regulation of intestinal epithelial cell growth by transforming growth factor type beta. 246 94